Alembic Pharma

43
Sell
  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE901L01018
  • NSEID: APLLTD
  • BSEID: 533573
INR
900.00
-2.2 (-0.24%)
BSENSE

Dec 05

BSE+NSE Vol: 34.54 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Consolidated - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
No of Months
12
12
12
12
12
12
Operating Income
6,672.00
6,228.00
5,652.00
5,305.00
5,393.00
4,605.00
Less :Inter divisional transfers
0.00
0.00
0.00
0.00
0.00
0.00
Less: Excise
0.00
0.00
0.00
0.00
0.00
0.00
Net Sales
6,672.00
6,228.00
5,652.00
5,305.00
5,393.00
4,605.00
Expenditure (Ex Depriciation)
Stock Adjustments
-289.00
-142.00
78.00
-43.00
-193.00
-210.00
Raw Materials Consumed
2,083.00
1,857.00
1,630.00
1,489.00
1,451.00
1,249.00
Power & Fuel Cost
179.00
173.00
151.00
120.00
118.00
102.00
Employee Cost
1,562.00
1,446.00
1,169.00
1,133.00
1,051.00
906.00
Operating Expenses
431.00
366.00
380.00
328.00
346.00
325.00
General and Administration Expenses
-1.00
-1.00
-1.00
-1.00
-1.00
-1.00
Selling and Distribution Expenses
1,064.00
996.00
952.00
890.00
696.00
531.00
Cost of Software developments
0.00
0.00
0.00
0.00
0.00
0.00
Miscellaneous Expenses
46.00
50.00
60.00
47.00
-44.00
95.00
Expenses Capitalised
0.00
0.00
0.00
0.00
0.00
0.00
Total Expenditure
5,663.00
5,295.00
4,944.00
4,431.00
3,835.00
3,382.00
Operating Profit (PBDIT) excl Other Income
1,008.00
933.00
708.00
874.00
1,557.00
1,223.00
Other Income
42.00
28.00
2.00
50.00
10.00
4.00
Operating Profit (PBDIT)
1,050.00
961.00
711.00
924.00
1,567.00
1,227.00
Interest
78.00
56.00
50.00
17.00
16.00
27.00
Profit before Depriciation and Tax
972.00
905.00
660.00
906.00
1,551.00
1,200.00
Depreciation
278.00
272.00
275.00
286.00
183.00
157.00
Profit Before Taxation & Exceptional Items
693.00
632.00
385.00
620.00
1,368.00
1,043.00
Exceptional Income / Expenses
0.00
0.00
0.00
0.00
0.00
0.00
Profit Before Tax
707.00
631.00
354.00
625.00
1,368.00
999.00
Provision for Tax
125.00
16.00
12.00
104.00
253.00
199.00
Profit After Tax
581.00
616.00
372.00
515.00
1,114.00
800.00
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
Adj to Profit After Tax
0.00
0.00
0.00
0.00
0.00
0.00
Profit Balance B/F
4,027.00
3,568.00
2,554.00
2,384.00
1,538.00
1,286.00
Profit Available for appropriations
4,610.00
4,184.00
2,896.00
2,905.00
2,716.00
2,115.00
Appropriations
4,610.00
4,184.00
2,896.00
2,905.00
2,716.00
2,115.00
Equity Dividend (%)
550.00%
550.00%
400.00%
500.00%
700.00%
500.00%
Earnings Per Share
29.68
31.33
17.40
26.50
60.81
43.97
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is 7.12% vs 10.19% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is 8.02% vs 31.76% in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is 40.19% vs 12.00% in Mar 2024

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2025 is -5.78% vs 65.40% in Mar 2024

Compare Profit and Loss Results of Alembic Pharma
Markets Mojo
Figures in Cr
consolidated - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
6,672.00
1,694.00
4,978.00
293.86%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
6,672.00
1,694.00
4,978.00
293.86%
Expenditure (Ex Depriciation)
Stock Adjustments
-289.00
4.00
-293.00
-7,325.00%
Raw Materials Consumed
2,083.00
460.00
1,623.00
352.83%
Power & Fuel Cost
179.00
48.00
131.00
272.92%
Employee Cost
1,562.00
549.00
1,013.00
184.52%
Operating Expenses
431.00
94.00
337.00
358.51%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
1,064.00
11.00
1,053.00
9,572.73%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
46.00
35.00
11.00
31.43%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
5,663.00
1,286.00
4,377.00
340.36%
Operating Profit (PBDIT) excl Other Income
1,008.00
407.00
601.00
147.67%
Other Income
42.00
36.00
6.00
16.67%
Operating Profit (PBDIT)
1,050.00
444.00
606.00
136.49%
Interest
78.00
78.00
0.00
0.00%
Profit before Depriciation and Tax
972.00
366.00
606.00
165.57%
Depreciation
278.00
138.00
140.00
101.45%
Profit Before Taxation & Exceptional Items
693.00
227.00
466.00
205.29%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
707.00
227.00
480.00
211.45%
Provision for Tax
125.00
57.00
68.00
119.30%
Profit After Tax
581.00
170.00
411.00
241.76%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
4,027.00
553.00
3,474.00
628.21%
Profit Available for appropriations
4,610.00
723.00
3,887.00
537.62%
Appropriations
4,610.00
723.00
3,887.00
537.62%
Equity Dividend (%)
550%
0%
550.00
Earnings Per Share
29.68
8.83
20.85
236.13%
Profit And Loss - Net Sales
Net Sales 6,672.08 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 7.12% vs 10.19% in Mar 2024

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 1,008.24 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 8.02% vs 31.76% in Mar 2024

Profit And Loss - Interest
Interest 78.77 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 40.19% vs 12.00% in Mar 2024

Profit And Loss - Profit After Tax
Profit After Tax 581.14 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is -5.78% vs 65.40% in Mar 2024